The company, which comprises BBInternational, BBI Enzymes and BBI Healthcare has generated significant revenue growth and currently has an annual turnover of £35 million. It supplies a global market place, currently employing over 300 staff across 6 sites in the UK, USA and South Africa.
Lyn joined the group in 1999 as Sales and Marketing Manager for BBInternational, the group’s diagnostics division, and was integral in the company’s strategic move from the life sciences and research arena into the £15 billion diagnostics market. Rising through the ranks of the commercial team, Lyn became Sales Director of the division and implemented strategies to grow BBInternational to be a market leader in reagent supply, contract manufacture and assay development.
In 2006 Lyn successfully set up BBI Healthcare, an innovative and ambitious company that supplies novel diabetes care products to domestic and international markets. He returned to BBInternational as CEO in late 2007 where he was responsible for achieving significant growth in terms of revenue and staffing levels.
The promotion to Group CEO means that in addition to BBInternational, Lyn is now responsible for BBI Healthcare and also BBI Enzymes, which specializes in the extraction and purification of natural enzymes. Lyn succeeds Julian Baines who was instrumental in the group’s success over the last decade.
Commenting on his appointment Lyn said:
"I am thrilled to have been given this opportunity and am committed to the further growth of the business and to building on a strong foundation created by Julian. I look forward to seeing further expansion across all divisions, whilst still maintaining BBI’s signature levels of customer service and product quality upon which we always pride ourselves."